Related Experiment Video

Updated: Dec 20, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K

Vivencio Barrios1, Carlos Escobar2, Juan José Gómez-Doblas3

  • 1Cardiology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Journal of Comparative Effectiveness Research
|May 30, 2020
PubMed

Insights

Patients with nonvalvular atrial fibrillation found dabigatran more convenient and satisfying than vitamin K antagonists over six months. This direct oral anticoagulant improved patient perception, with low discontinuation rates due to side effects.

Area of Science:

  • Cardiology
  • Pharmacology
  • Patient-Reported Outcomes

Background:

  • Nonvalvular atrial fibrillation (NVAF) necessitates anticoagulation to prevent stroke.
  • Vitamin K antagonists (VKAs) are traditional anticoagulants with limitations.
  • Dabigatran, a direct oral anticoagulant (DOAC), offers an alternative treatment option.

Purpose of the Study:

  • To evaluate patient perceptions of dabigatran therapy compared to prior VKA treatment.
  • To assess changes in convenience and satisfaction scores over a 6-month period.
  • To analyze factors influencing patient satisfaction and convenience with dabigatran.

Main Methods:

  • Prospective, noninterventional, multicenter study design.
  • Inclusion of 659 patients with NVAF previously treated with VKAs.
  • Assessment of patient perceptions using the PACT-Q2 questionnaire.

Main Results:

  • Significant increases in convenience and satisfaction scores were observed over 6 months.
  • Higher convenience scores noted in males and patients with low-moderate thromboembolic risk.
  • Higher satisfaction scores reported by female patients; only 8.0% discontinued dabigatran.

Conclusions:

  • Dabigatran demonstrated superior convenience and satisfaction compared to VKAs in NVAF patients.
  • The study highlights improved patient-reported outcomes with dabigatran therapy.
  • Low discontinuation rates suggest good tolerability and adherence to dabigatran.

Keywords:
PACT-Q2 questionnaireatrial fibrillationdabigatransatisfactiontreatment convenience

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.8K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.7K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
205
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
945
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
214
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.4K